Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in advanced pancreatic neuroendocrine tumors
NCT02589821Phase 3Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2015
- Primary completion
- Nov 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pancreatic neuroendocrine tumor (PanNET) comparing Surufatinib with Placebo (2 arms). Primary endpoint: Progression Free Survival. Started Dec 2015; status: completed.
02
Drugs
surufatinib
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02589821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589821.